[(2S)-6-azaniumyl-1-oxo-1-[[(2S)-1-phenylpropan-2-yl]amino]hexan-2-yl]azanium;methanesulfonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2S)-6-azaniumyl-1-oxo-1-[[(2S)-1-phenylpropan-2-yl]amino]hexan-2-yl]azanium;methanesulfonate
• 化学式: C17H33N3O7S2
• 分子量: 455.6
• InChiKey: CETWSOHVEGTIBR-FORAGAHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  207
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  [5-tert-butoxycarbonylamino-5-(1-methyl-2-phenylethylcarbamoyl)pentyl]carbamic acid tert-butyl ester 以95的产率得到[(2S)-6-azaniumyl-1-oxo-1-[[(2S)-1-phenylpropan-2-yl]amino]hexan-2-yl]azanium;methanesulfonate
  参考文献：
  名称：

  [EN] PROCESS FOR THE SYNTHESIS OF AMPHETAMINE DERIVATIVES
  [FR] PROCÉDÉ POUR LA SYNTHÈSE DE DÉRIVÉS D'AMPHÉTAMINE

  摘要：

  本发明涉及一种制备酰化苯丙胺、甲基苯丙胺和地西泮衍生物的方法，通过将母体胺与待偶合酸或待偶合酸的盐（该酸受到保护或未受到保护）在烷基膦酸酐偶联剂的存在下反应，以及（如果酸（V2）受到保护）保护基的解除，在一个反应罐中或在两个或多个分离的步骤中进行。

  公开号：

  WO2010042120A1

文献信息

• [EN] ABUSE RESISTANT AMPHETAMINE COMPOUNDS<br/>[FR] COMPOSES D'AMPHETAMINE RESISTANT AUX ABUS
  申请人：NEW RIVER PHARMACEUTICALS INC

  公开号：WO2005000334A1

  公开（公告）日：2005-01-06

  The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

  本发明涉及一种将化学基团共价连接到苯丙胺的化合物、组合物和使用方法。这些化合物和组合物可用于减少或预防苯丙胺的滥用和过量使用。这些化合物和组合物在为某些疾病提供抗滥用替代治疗方面具有特殊用途，例如注意力缺陷多动障碍（ADHD）、ADD、嗜睡症和肥胖症。在治疗上，苯丙胺的口服生物利用度保持在治疗上有用的剂量。在更高剂量下，生物利用度显著降低，从而提供了一种减少口服滥用风险的方法。此外，本发明的化合物和组合物通过静脉或鼻腔给药等肌肉注射途径进一步降低苯丙胺的生物利用度，从而进一步限制其滥用风险。
• [EN] PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES POUR PREVENIR UNE DOSE EXCESSIVE OU UN ABUS
  申请人：NEW RIVER PHARMACEUTICALS INC

  公开号：WO2005032474A2

  公开（公告）日：2005-04-14

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及制药组合物，该组合物由化学基团与活性药物以一种方式结合，从而大大降低了活性药物引起过量或滥用的潜力。当以适当的剂量给予该制药组合物时，其提供的治疗活性与原始活性药物相似。
• Abuse resistant lysine amphetamine compounds
  申请人：Shire LLC

  公开号：US07662787B2

  公开（公告）日：2010-02-16

  The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

  本发明描述了一种将赖氨酸共价连接到苯丙胺的化合物、组合物和使用方法。这些化合物和组合物有助于减少或预防苯丙胺的滥用和过量使用。这些化合物和组合物在为某些疾病提供抗滥用的替代治疗方案方面具有特殊用途，例如注意力缺陷多动障碍（ADHD）、ADD、嗜睡症和肥胖症。在治疗剂量下，苯丙胺的口服生物利用度得以维持，而在更高剂量下，生物利用度显著降低，从而提供了一种减少口服滥用风险的方法。此外，本发明的化合物和组合物通过静脉或鼻腔给药途径降低了苯丙胺的生物利用度，进一步限制了它们的滥用风险。
• [EN] PROCESS FOR THE SYNTHESIS OF AMPHETAMINE DERIVATIVES<br/>[FR] PROCÉDÉ POUR LA SYNTHÈSE DE DÉRIVÉS D'AMPHÉTAMINE
  申请人：ARCHIMICA INC

  公开号：WO2010042120A1

  公开（公告）日：2010-04-15

  The invention relates to a process for preparing acylated amphetamine, methamphetamine and dexamphetamine derivatives by reacting the parent amine with the to be coupled acid or a salt of the to be coupled acid which acid is protected or not protected, in the presence of an alkylphosphonic acid anhydride as coupling agent and - provided the acid (V2) was protected - the cleavage of the protecting group(s), in a one-pot reaction or in two or more separate steps.

  本发明涉及一种制备酰化苯丙胺、甲基苯丙胺和地西泮衍生物的方法，通过将母体胺与待偶合酸或待偶合酸的盐（该酸受到保护或未受到保护）在烷基膦酸酐偶联剂的存在下反应，以及（如果酸（V2）受到保护）保护基的解除，在一个反应罐中或在两个或多个分离的步骤中进行。
• ABUSE-RESISTANT AMPHETAMINE PRODRUGS
  申请人：Mickle Travis

  公开号：US20090124700A1

  公开（公告）日：2009-05-14

  The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

  本发明描述了一种将化学基团共价连接到苯丙胺上的化合物、组合物及其使用方法。这些化合物和组合物有助于减少或预防苯丙胺的滥用和过量使用。这些化合物和组合物在提供一种抗滥用的替代治疗某些疾病，如注意力缺陷多动障碍（ADHD）、ADD、嗜睡症和肥胖症等方面发挥特殊作用。在治疗剂量下，苯丙胺的口服生物利用度得以维持。在更高剂量下，生物利用度大大降低，从而提供了一种减少口服滥用风险的方法。此外，本发明的化合物和组合物通过静脉或鼻腔给药等肠外途径进一步降低苯丙胺的生物利用度，进一步限制了它们的滥用风险。